Fresenius Medical Care Q3 Operating Income Down 19%, FY2026 Outlook Narrowed
FMS is trading near its 52-week low of $20.02 (15% above the low).
Summary
Fresenius Medical Care reported Q3 2026 revenue of EUR 4,937M (+1%), but operating income fell 19% to EUR 384M on EUR 108M of China restructuring costs, and the company narrowed its FY2026 operating income outlook to flat to negative mid-single digit growth.
Key Events · Earnings and Guidance · FMS
-
Q3 Revenue Roughly Flat
Revenue was EUR 4,937M, up 1% reported but down 1% at constant currency and up only 0.1% organic; Care Delivery grew 3% while Value-Based Care fell 7%.
-
Operating Income Falls 19%
Reported operating income was EUR 384M versus EUR 477M a year ago; excluding special items it was EUR 545M, down 5%, for an 11.0% margin versus 11.7%.
-
China Exit Drives EUR 108M Charge
Discontinuing local 4008A production and exiting the peritoneal dialysis business produced EUR 108M of one-time costs, mostly impairments and termination costs, pushing Care Enablement to a EUR 32M operating loss.
-
FY2026 Outlook Narrowed
Operating income growth is now guided to flat to negative mid-single digit percent at constant currency, versus a 2025 base of EUR 2,212M; revenue is still expected broadly flat against EUR 19,628M.
Analysis · FMS · Industrial Applications And Services
The headline hit is severe: reported operating income fell 19% to EUR 384M and net income dropped 42% to EUR 160M, largely because of EUR 108M in one-time costs from the China strategy refinement. Strip out special items and the picture steadies — operating income of EUR 545M was down 5% and EPS of EUR 1.11 was flat. Even so, management cut the full-year operating income outlook to flat to negative mid-single digit growth, a signal that TDAPA reimbursement headwinds and inflation are biting harder than previously planned. Cash generation remains the offset: free cash flow rose 3% to EUR 564M in the quarter and net leverage held at 2.6x, near the low end of the 2.5x-3.0x target band.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, FMS was trading at $23.02 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $12B. The 52-week trading range was $20.02 to $26.95. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.